Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 38, Issue 10, 2008, Pages 689-694

  Machida, Nozomu ^a   Yoshino, Takayuki ^a   Boku, Narikazu ^a   Hironaka, Shuichi ^a   Onozawa, Yusuke ^a   Fukutomi, Akira ^a   Yamazaki, Kentaro ^a   Yasui, Hirofumi ^a   Taku, Keisei ^a   Asaka, Masahiro ^b  

^a SHIZUOKA CANCER CENTER   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Prognostic factor; RECIST

Indexed keywords

ALKALINE PHOSPHATASE; CARCINOEMBRYONIC ANTIGEN; COLONY STIMULATING FACTOR; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; UFT;

ADULT; AGED; ARTICLE; ASCITES; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERITONEUM METASTASIS; PLEURA EFFUSION; PROGNOSIS; SOLID TUMOR; SURVIVAL TIME; TUMOR VOLUME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 54949116540     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn086     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. August DA, Sugarbaker PH, Ottow RT, et al. Hepatic resection of colorectal metastases: Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg 1985;201:210-8.
3. Yoshimi I, Sobue T. Current status and trends in cancer mortality in Japan. Gan To Kagaku Ryoho 2004;31:832-9.
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
5. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
6. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:129a.
7. Tournigand C, Andre T, Achille E, et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR Study. J Clin Oncol 2004;22:229-37.
8. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of Fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
9. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
10. Köhne CH, Van Cutsem E, Wils JA, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-65.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
12. Hurwitz Herbert I, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23: 3502-8.
13. Köhne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17.
14. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
15. Knight R, Miller L, Pirotta N, et al. First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators. Proc Am Soc Clin Oncol 2000;19:255a.
16. Assersohn L, Norman A, Cunningham D, et al. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999;79:1800-5.
17. Kouri M, Pyrhonen S, Kuusela P, et al. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992;49:78-85.
18. Steinberg J, Erlichman C, Gadalla T, et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 1992;28A:1817-20.
19. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM, et al. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 1986;57:1866-70.
20. Kemeny N, Braun DW, Jr, et al. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med 1983; 74:786-94.
21. Mitry E, Douillard J-Y, et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15: 1013-7.
22. Chang AE, Steinberg SM, Culnane M, White DE, et al. Determinants of survival in patients with unresectable colorectal liver metastases. J Surg Oncol 1989;40:245-51.
23. Hurwitz Zurlo A, et al. Analysis of outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) in a phase III clinical trial based on baseline risk. Proc Am Soc Clin Oncol 2006.
24. Webb A, Scott-Mackie P, Cunningham D, et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 1995;6:581-7.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.